ARCHIVES

Benefit Seen In Novel Drug That Treats Gleevec Resistance

This article is from The Cancer Letter archive.

Vol. 28 No. 4 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.

December 10, 2004

Abstract Of Papers From ACTR Meeting

October 22, 1976

Breast Cancer Coalition Widens Its Agenda For Advocacy, Vows To Fight NIH Cutbacks

May 5, 1995

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

FDA Pettiness Holds Up Trials with Promising Anticancer Drugs

November 14, 1975

VEGF Levels Can Predict Tumor’s Resistance to Avastin

July 29, 2011